Activity-dependent neuroprotective protein: From gene to drug candidate

Pharmacology and Therapeutics

Volumn 114, Issue 2, 2007, Pages 146-154

  Gozes, Illana ^a,b,c  

^a Laboratory for Molecular Neuroendocrinology ^*  (Israel)

^b Laboratory for Molecular Neuroendocrinology   (United States)

^c Allon Therapeutics Inc   (Canada)

Author keywords

Activity dependent neuroprotective protein; Glial cells; Neuroprotection; Vasoactive intestinal peptide

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; ALANINE; ASPARAGINE; GENE PRODUCT; GLUTAMINE; ISOLEUCINE; MESSENGER RNA; PROLINE; SERINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; BRAIN DEVELOPMENT; BRAIN INJURY; BRAIN PROTECTION; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENCY; ESTRUS CYCLE; FETAL ALCOHOL SYNDROME; GENE EXPRESSION; GENETIC CONSERVATION; HEAD INJURY; HOMEOBOX; HORMONAL REGULATION; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 34147210784     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.01.004     Document Type: Review

References (68)

1. Alcalay R.N., Giladi E., Pick C.G., and Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361 (2004) 128-131
2. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72 (1999) 1283-1293
3. Beni-Adani L., Gozes I., Cohen Y., Assaf Y., Steingart R.A., Brenneman D.E., et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296 (2001) 57-63
4. Blondel O., Collin C., McCarran W.J., Zhu S., Zamostiano R., Gozes I., et al. A glia-derived signal regulating neuronal differentiation. J Neurosci 20 (2000) 8012-8020
5. Brenneman D.E., and Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 97 (1996) 2299-2307
6. Brenneman D.E., Hauser J., Neale E., Rubinraut S., Fridkin M., Davidson A., et al. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285 (1998) 619-627
7. Burkhart C.A., Kavallaris M., and Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471 (2001) O1-O9
8. Cashion A.B., Smith M.J., and Wise P.M. The morphometry of astrocytes in the rostral preoptic area exhibits a diurnal rhythm on proestrus: relationship to the luteinizing hormone surge and effects of age. Endocrinology 144 (2003) 274-280
9. Chen S., Pickard J.D., and Harris N.G. Time course of cellular pathology after controlled cortical impact injury. Exp Neurol 182 (2003) 87-102
10. Chen S.Y., Charness M.E., Wilkemeyer M.F., and Sulik K.K. Peptide-mediated protection from ethanol-induced neural tube defects. Dev Neurosci 27 (2005) 13-19
11. Dangoor D., Giladi E., Fridkin M., and Gozes I. Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides 26 (2005) 2579-2584
12. Divinski I., Mittelman L., and Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279 (2004) 28531-28538
13. Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R.A., and Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98 (2006) 973-984
14. Ferlini C., Raspaglio G., Mozzetti S., Cicchillitti L., Filippetti F., Gallo D., et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65 (2005) 2397-2405
15. Fleisher A., Grundman M., Jack Jr. C.R., Petersen R.C., Taylor C., Kim H.T., et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 62 (2005) 953-957
16. Furman S., Steingart R.A., Mandel S., Hauser J.M., Brenneman D.E., and Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 1 (2004) 193-199
17. Furman S., Hill J.M., Vulih I., Zaltzman R., Hauser J.M., Brenneman D.E., et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 373 (2005) 73-78
18. Gerhold L.M., and Wise P.M. Vasoactive intestinal polypeptide regulates dynamic changes in astrocyte morphometry: impact on gonadotropin-releasing hormone neurons. Endocrinology 147 (2006) 2197-2202
19. Gozes I., and Barnstable C.J. Monoclonal antibodies that recognize discrete forms of tubulin. Proc Natl Acad Sci U S A 79 (1982) 2579-2583
20. Gozes I., and Brenneman D.E. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?. J Mol Neurosci 7 (1996) 235-244
21. Gozes I., and Brenneman D.E. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 14 (2000) 61-68
22. Gozes I., and Divinski I. The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J Alzheimers Dis 6 (2004) S37-S41
23. Gozes I., and Furman S. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract Res Clin Endocrinol Metab 18 (2004) 623-640
24. Gozes I., and Littauer U.Z. Tubulin microheterogeneity increases with rat brain maturation. Nature 276 (1978) 411-413
25. Gozes I., and Sweadner K.J. Multiple tubulin forms are expressed by a single neurone. Nature 294 (1981) 477-480
26. Gozes I., Giladi E., Pinhasov A., Bardea A., and Brenneman D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293 (2000) 1091-1098
27. Gozes I., Zamostiano R., Pinhasov A., Bassan M., Giladi E., Steingart R.A., et al. A novel VIP-responsive gene. Activity dependent neuroprotective protein. Ann N Y Acad Sci 921 (2000) 115-118
28. Gozes I., Alcalay R., Giladi E., Pinhasov A., Furman S., and Brenneman D.E. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 19 (2002) 167-170
29. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., and Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20 (2003) 315-322
30. Gozes I., Steingart R.A., and Spier A.D. NAP mechanisms of neuroprotection. J Mol Neurosci 24 (2004) 67-72
31. Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11 (2005) 353-368
32. Gozes I., Zaltzman R., Hauser J., Brenneman D.E., Shohami E., and Hill J.M. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2 (2005) 149-153
33. Hevner R.F., Hodge R.D., Daza R.A., and Englund C. Transcription factors in glutamatergic neurogenesis: conserved programs in neocortex, cerebellum, and adult hippocampus. Neurosci Res 55 (2006) 223-233
34. Hou Y., Yang S.P., and Voogt J.L. Changes in estrogen receptor-alpha expression in hypothalamic dopaminergic neurons during proestrous prolactin surge. Endocrine 20 (2003) 131-138
35. Hung A.J., Stanbury M.G., Shanabrough M., Horvath T.L., Garcia-Segura L.M., and Naftolin F. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Exp Gerontol 38 (2003) 53-59
36. Katsetos C.D., Herman M.M., and Mork S.J. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55 (2003) 77-96
37. Kriegsfeld L.J., Silver R., Gore A.C., and Crews D. Vasoactive intestinal polypeptide contacts on gonadotropin-releasing hormone neurones increase following puberty in female rats. J Neuroendocrinol 14 (2002) 685-690
38. Leker R.R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M., et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33 (2002) 1085-1092
39. Li M., David C., Kikuta T., Somogyvari-Vigh A., and Arimura A. Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J Mol Neurosci 27 (2005) 91-105
40. Lutz E.M., Ronaldson E., Shaw P., Johnson M.S., Holland P.J., and Mitchell R. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol Cell Neurosci 31 (2006) 193-209
41. Magie C.R., and Parkhurst S.M. Rho1 regulates signaling events required for proper Drosophila embryonic development. Dev Biol 278 (2005) 144-154
42. Magnani M., Ortuso F., Soro S., Alcaro S., Tramontano A., and Botta M. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents, Docking and molecular dynamics studies. FEBS J 273 (2006) 3301-3310
43. Mandel S, Rechavi G & Gozes I: Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol. 2006 Dec 1; [Epub ahead of print].
44. Michaelis M.L., Ansar S., Chen Y., Reiff E.R., Seyb K.I., Himes R.H., et al. {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 48 (2004) 832-838
45. Mitsushima D., Tin Tin Win S., and Kimura F. Sexual dimorphism in the GABAergic control of gonadotropin release in intact rats. Neurosci Res 46 (2003) 399-405
46. Nakamachi T., Li M., Shioda S., and Arimura A. Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression. Peptides 27 (2006) 1859-1864
47. Pilzer I., and Gozes I. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides 27 (2006) 2867-2876
48. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A.M., et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144 (2003) 83-90
49. Poggi S.H., Vink J., Goodwin K., Hill J.M., Brenneman D.E., Pinhasov A., et al. Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. Am J Obstet Gynecol 187 (2002) 973-976
50. Poggi S.H., Goodwin K., Hill J.M., Brenneman D.E., Tendi E., Schinelli S., et al. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 189 (2003) 790-793
51. Porkka-Heiskanen T., Kalinchuk A., Alanko L., Huhtaniemi I., and Stenberg D. Orexin A and B levels in the hypothalamus of female rats: the effects of the estrous cycle and age. Eur J Endocrinol 150 (2004) 737-742
52. Qu J.H., Cheng J., Zhang L.X., Zhong Y.W., Liu Y., Wang L., et al. Screening of binding proteins to interferon-alpha promoter DNA by phage display technique. Zhonghua Gan Zang Bing Za Zhi 13 (2005) 520-523
53. Quintana F.J., Zaltzman R., Fernandez-Montesinos R., Herrera J.L., Gozes I., Cohen I.R., et al. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci 1070 (2006) 500-506
54. Romano J., Beni-Adani L., Nissenbaum O.L., Brenneman D.E., Shohami E., and Gozes I. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci (2002) 37-45
55. Rotstein M., Bassan H., Kariv N., Speiser Z., Harel S., and Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E deficient mice subjected to hypoxia. J Pharmacol Exp Ther 319 (2006) 332-339 (Erratum in: J Pharmacol Exp Ther. 2007; 320, 498)
56. Sari Y., and Gozes I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Brain Res Rev 52 (2006) 107-118
57. Selmi C., Lleo A., Zuin M., Podda M., Rossaro L., and Gershwin M.E. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 7 (2006) 451-456
58. Sigalov E., Fridkin M., Brenneman D.E., and Gozes I. VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci 15 (2000) 147-154
59. Smith M.J., and Jennes L. Neural signals that regulate GnRH neurones directly during the oestrous cycle. Reproduction 122 (2001) 1-10
60. Sohur U.S., Emsley J.G., Mitchell B.D., and Macklis J.D. Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells. Philos Trans R Soc Lond B Biol Sci 361 (2006) 1477-1497
61. Spong C.Y., Abebe D.T., Gozes I., Brenneman D.E., and Hill J.M. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297 (2001) 774-779
62. Steingart R.A., and Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 252 (2006) 148-153
63. van den Top M., Lee K., Whyment A.D., Blanks A.M., and Spanswick D. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. Nat Neurosci 7 (2004) 493-494
64. Zaltzman R., Beni S.M., Giladi E., Pinhasov A., Steingart R.A., Romano J., et al. Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport 14 (2003) 481-484
65. Zaltzman R., Alexandrovich A., Beni S.M., Trembovler V., Shohami E., and Gozes I. Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci 24 (2004) 181-187
66. Zaltzman R., Alexandrovich A., Trembovler V., Shohami E., and Gozes I. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides 26 (2005) 1520-1527
67. Zamostiano R., Pinhasov A., Gelber E., Steingart R.A., Seroussi E., Giladi E., et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276 (2001) 708-714
68. Zusev M., and Gozes I. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 123 (2004) 33-41